第三代抗血小板药普拉格雷

Prasugrel,a third generation antiplatelet agent

美国食品药品监督管理局(FDA)于2009年7月9日批准了由美国礼来公司与日本第一三共制药公司共同研发的噻吩吡啶类新型抗血小板药盐酸普拉格雷(prasugrel hydrochloride,商品名:Effient)上市。盐酸普拉格雷为第三代抗血小板药,与第二代抗血小板药氯吡格雷(clopidogrel,Plavix/Iscover)相比,具有作用更快、更强、更持久、更安全的特点,但其出血问题应引起高度关注,应权衡利弊严格掌握适应症谨慎使用。文中对其药动学、药效学特点及不良反应等做一介绍。

Prasugrel hydrochloride（Effient）,an antiplatelet agent of thienopyridine that was approved by FDA on 9th July,2009,is a potent,selective and irreversible inhibitor of adenosine diphosphate（ADP）-mediated platelet aggregation.In comparison to clopidogrel,recent studies have demonstrated that prasugrel achieves a faster,higher and more consistent level of inhibition of platelet aggregation.Bleeding events were the most frequently reported adverse events associated with prasugrel treatment including the incidence of life-threatening bleeding and fatal bleeding events.The pharmacokinetics,pharmacodynamic characteristics and adverse reactions of prasugrel were reviewed.